keyword
MENU ▼
Read by QxMD icon Read
search

sulfonylureas

keyword
https://www.readbyqxmd.com/read/29328551/failure-of-monotherapy-in-clinical-practice-in-patients-with-type-2-diabetes-the-korea-national-diabetes-program
#1
Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan-Woo Lee
AIMS: We investigated the failure of monotherapy in patients with type 2 DM in real practice settings. METHODS: The Korea National Diabetes Program was a prospective, multicenter observational cohort study of type 2 DM patients in Korea. Of the 3,950 patients enrolled in the study, we studied 998 who were continuously maintained on monotherapy for at least 90 days at six participating centers. To balance the baseline characteristics of patients in each group, we employed propensity-matching at a 1:1 ratio (metformin vs...
January 12, 2018: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29327406/short-and-medium-term-efficacy-of-sodium-glucose-co-transporter-2-sglt-2-inhibitors-a-meta-analysis-of-randomized-clinical-trials
#2
Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu, Edoardo Mannucci
AIMS: Sodium glucose co-transport-2 (SGLT-2) inhibitors reduce tubular glucose reabsorption, producing a reduction of blood glucose without stimulating insulin release. Aim of this meta-analysis is the systematic collection of available data from randomized trials, in order to establish the durability of the efficacy of SGLT-2 inhibitors on glycemic control and body mass index. METHODS: A meta-analysis was performed including all trials with a duration of at least 12 weeks, comparing SGLT-2 inhibitors with a non-SGLT-2 inhibitor agents in type 2 diabetes...
January 12, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29326107/tcf7l2-genetic-variation-augments-incretin-resistance-and-influences-response-to-a-sulfonylurea-and-metformin-the-study-to-understand-the-genetics-of-the-acute-response-to-metformin-and-glipizide-in-humans-sugar-mgh
#3
Shylaja Srinivasan, Varinderpal Kaur, Bindu Chamarthi, Katherine R Littleton, Ling Chen, Alisa K Manning, Jordi Merino, Melissa K Thomas, Margo Hudson, Allison Goldfine, Jose C Florez
OBJECTIVE: The rs7903146 T allele in transcription-factor-7-like-2 (TCF7L2) is strongly associated with type 2 diabetes (T2D), but the mechanisms for increased risk remain unclear. We evaluated the physiologic and hormonal effects of TCF7L2 genotype before and after interventions that influence glucose physiology. RESEARCH DESIGN AND METHODS: We genotyped rs7903146 in 608 individuals without diabetes and recorded biochemical data before and after one dose of glipizide (5 mg) on visit 1, and a 75-g oral glucose tolerance test (OGTT) performed after administration of metformin 500 mg twice daily over 2 days...
January 11, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29320889/the-cardiovascular-effect-of-incretin-based-therapies-among-type-2-diabetes-a-systematic-review-and-network-meta-analysis
#4
Shanshan Wu, Andrea Cipriani, Zhirong Yang, Jun Yang, Ting Cai, Yang Xu, Xiaochi Quan, Yuan Zhang, Sanbao Chai, Feng Sun, Siyan Zhan
OBJECTIVE: To evaluate the comparative cardiovascular safety of incretin-based therapies in patients with type 2 diabetes mellitus (T2DM). METHODS: Medline, Embase, the Cochrane Library and www.clinicaltrials.gov were searched for randomized controlled trials (RCTs) with duration≥12 weeks. Network meta-analysis was performed, followed by subgroup analysis and meta-regression. The Grading of Recommendations Assessment, Development and Evaluation system was used to assess the quality of evidence...
January 10, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29319909/inhibitory-effects-of-sulfonylureas-and-non-steroidal-anti-inflammatory-drugs-on-in-vitro-metabolism-of-canagliflozin-in-human-liver-microsomes
#5
Sara Algeelani, Dalal Alkhelb, David J Greenblatt
Canagliflozin, used to treat type 2 diabetes mellitus (T2DM), is commonly co-administered with sulfonylureas. The objective of the present study was to evaluate the possible inhibitory effect of sulfonylureas and non-steroidal anti-inflammatory drugs (NSAIDs) on canagliflozin metabolism in vitro. Three sulfonylurea derivatives were evaluated as inhibitors: chlorpropamide, glimepiride, and gliclazide. Two other NSAIDs were used as positive control inhibitors: niflumic acid and diclofenac. The rate of formation of canagliflozin metabolites was determined by HPLC analysis of vitro incubations of canagliflozin as a substrate with and without inhibitors, using human liver microsomes (HLMs)...
January 10, 2018: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/29305569/emergence-of-insulin-resistance-following-empirical-glibenclamide-therapy-a-case-report-of-neonatal-diabetes-with-a-recessive-ins-gene-mutation
#6
Melek Yildiz, Teoman Akcay, Banu Aydin, Abdurrahman Akgun, Beyza Belde Dogan, Elisa De Franco, Sian Ellard, Hasan Onal
BACKGROUND: As KATP channel mutations are the most common cause of neonatal diabetes mellitus (NDM) and patients with these mutations can be treated with oral sulfonylureas, empiric therapy is a common practice for NDM patients. CASE PRESENTATION: A non-syndromic, small for gestational age baby born to first-degree consanguineous parents was diagnosed with NDM. Because of hypo- and hyperglycemic episodes and variability in insulin requirement, we initiated a trial of glibenclamide, with a presumptive diagnosis of NDM caused by a KATP channel mutation...
January 6, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/29302934/a-class-comparison-of-medication-persistence-in-people-with-type-2-diabetes-a-retrospective-observational-study
#7
Andrew McGovern, William Hinton, Silvio Calderara, Neil Munro, Martin Whyte, Simon de Lusignan
INTRODUCTION: Longer medication persistence in type 2 diabetes (T2D) is associated with improved glycaemic control. It is not clear which oral therapies have the best persistence. The objective of this study was to compare medication persistence across different oral therapies in people with T2D. METHODS: We performed a retrospective cohort analysis using a primary-care-based population, the Royal College of General Practitioners Research and Surveillance Centre cohort...
January 4, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29301824/clinical-impact-of-itca-650-a-novel-drug-device-glp-1-receptor-agonist-in-uncontrolled-type-2-diabetes-and-very-high-baseline-hba1c-the-freedom-1-hbl-study
#8
Robert R Henry, Julio Rosenstock, Douglas S Denham, Prakash Prabhakar, Lise Kjems, Michelle A Baron
OBJECTIVE: ITCA 650 is a subdermal osmotic mini-pump that continuously delivers exenatide subcutaneously for 3-6 months. The efficacy, safety, and tolerability of ITCA 650 added to diet and exercise alone or combined with metformin, sulfonylurea, or thiazolidinedione monotherapy or a combination of these drugs was evaluated in poorly controlled patients with type 2 diabetes (T2D) who were ineligible for participation in a placebo-controlled study (FREEDOM-1) because of severe hyperglycemia (HbA1c >10% [86 mmol/mol])...
January 4, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29296562/the-potential-for-interaction-of-tolbutamide-with-pomegranate-juice-against-diabetic-induced-complications-in-rats
#9
Manodeep Chakraborty, Mohammed Gulzar Ahmed, Ananya Bhattacharjee
Background: Pomegranate can inhibit cytochrome P450 (CYP) 2C9 activity, which is largely responsible for the metabolism of sulfonylureas. The present study was undertaken to evaluate the pharmacokinetic and pharmacodynamic interaction of pomegranate and tolbutamide (TOL) against diabetic-induced complications. Methods: Diabetes was induced via administration of alloxan (150 mg/kg, intraperitoneally). Rats (n = 8) were treated with pomegranate juice (PJ) [3 mL/animal, per os (p...
December 2017: Integrative Medicine Research
https://www.readbyqxmd.com/read/29296240/sulfonylurea-for-the-treatment-of-neonatal-diabetes-owing-to-katp-channel-mutations-a-systematic-review-and-meta-analysis
#10
Hongliang Zhang, Xiaobin Zhong, Zhenguang Huang, Chun Huang, Taotao Liu, Yue Qiu
The effect of sulfonylurea for the treatment of neonatal diabetes (NDM) is remain uncertain. We conducted this systematic review and meta-analysis to investigate the effect of sulfonylurea for NDM and to provide the latest and most convincing evidence for developing clinical practice guidelines of NDM. A literature review was performed to identify all published studies reporting the sulfonylurea on the treatment of neonatal diabetes. The search included the following databases: PUBMED, EMBASE and the Cochrane Library...
December 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/29291445/design-synthesis-and-biological-evaluation-of-novel-ring-opened-cromakalim-analogues-with-relaxant-effects-on-vascular-and-respiratory-smooth-muscles-and-as-stimulators-of-elastin-synthesis
#11
Mourad Bouhedja, Basile Peres, Wassim Fhayli, Zeinab Ghandour, Ahcène Boumendjel, Gilles Faury, Smail Khelili
Two new series of ring-opened analogues of cromakalim bearing sulfonylurea moieties (series A: with N-unmethylated sulfonylureas, series B: with N-methylated sulfonylureas) were synthesized and tested as relaxants of vascular and respiratory smooth muscles (rat aorta and trachea, respectively). Ex vivo biological evaluations indicated that the most active compounds, belonging to series B, displayed a marked vasorelaxant activity on endothelium-intact aortic rings and the trachea. A majority of series B compounds exhibited a higher vasorelaxant activity (EC50 < 22 μM) than that of the reference compound diazoxide (EC50 = 24 μM)...
December 21, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29285461/sulfonylureas-scoring-beyond-start-study
#12
Altamash Shaikh
No abstract text is available yet for this article.
November 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29283894/incretin-based-drugs-and-the-incidence-of-colorectal-cancer-in-patients-with-type-2-diabetes
#13
Devin Abrahami, Hui Yin, Oriana H Y Yu, Michael N Pollak, Laurent Azoulay
BACKGROUND: Evidence on the safety of the incretin-based drugs (glucagon-like peptide-1 [GLP-1] analogues and dipeptidyl peptidase-4 [DPP-4] inhibitors) with respect to colorectal cancer is contradictory. The objective of this study was to determine whether use of incretin-based drugs is associated with risk of incident colorectal cancer in patients with type 2 diabetes. METHODS: Using data from the United Kingdom Clinical Practice Research Datalink, we identified a cohort of 112,040 patients newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2015...
December 26, 2017: Epidemiology
https://www.readbyqxmd.com/read/29279487/changes-in-antidiabetic-drug-prescription-and-glycemic-control-trends-in-elderly-patients-with-type-2-diabetes-mellitus-from-2005-2013-an-analysis-of-the-national-center-diabetes-database-ncdd-03
#14
Ritsuko Yamamoto-Honda, Yoshihiko Takahashi, Yasumichi Mori, Shigeo Yamashita, Yoko Yoshida, Shoji Kawazu, Yasuhiko Iwamoto, Hiroshi Kajio, Hidekatsu Yanai, Shuichi Mishima, Nobuhiro Handa, Kotaro Shimokawa, Akiko Yoshida, Hiroki Watanabe, Kazuhiko Ohe, Takuro Shimbo, Mitsuhiko Noda
Objective To analyze the changes in the pharmacotherapy and glycemic control trends in elderly patients with type 2 diabetes mellitus (T2DM) in Japan. Materials and Methods We extracted the data of 7,590 patients (5,396 men and 2,194 women; median year of birth: 1945) with T2DM registered in the National Center Diabetes Database for the years 2005 to 2013, and conducted age-stratified (<65, 65-74, and ≥75 years of age) analyses. Results The hemoglobin A1c (HbA1c) levels declined from 2005 to 2013, and for those who received antihyperglycemic drug prescription, the HbA1c levels were lower in the older age group than in the younger age group...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29278452/sulfonylurea-vs-insulin-therapy-in-individuals-with-sulfonylurea-sensitive-permanent-neonatal-diabetes-mellitus-attributable-to-a-kcnj11-mutation-and-poor-glycaemic-control
#15
J Stanik, A Dankovcikova, L Barak, M Skopkova, M Palko, J Divinec, I Klimes, D Gasperikova
BACKGROUND: Therapy with sulfonylurea is preferable to insulin in the majority of individuals with KCNJ11 mutations, but not all of these people achieve target levels of HbA1c in long-term follow-up. We aimed to compare sulfonylurea therapy with insulin treatment in two sulfonylurea-sensitive individuals with a KCNJ11 mutation who had poorly controlled permanent neonatal diabetes mellitus. CASE REPORT: We report on two individuals with a KCNJ11 mutation (p.R201H) who are currently aged 35 (SVK1) and 21 years (SVK2)...
December 26, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/29275331/cantu-syndrome-associated-sur2-abcc9-mutations-in-distinct-structural-domains-result-in-katp-channel-gain-of-function-by-differential-mechanisms
#16
Conor McClenaghan, Alex Hanson, Monica Sala-Rabanal, Helen I Roessler, Dragana Josifova, Dorothy K Grange, Gijs van Haaften, Colin G Nichols
The complex cardiovascular disorder Cantu syndrome (CS) arises from gain-of-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively. Recent reports indicate that such mutations can increase channel activity by multiple molecular mechanisms. In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/W in TMD2...
December 22, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29258886/the-risk-of-fragility-fractures-in-new-users-of-dipeptidyl-peptidase-4-inhibitors-compared-to-sulfonylureas-and-other-anti-diabetic-drugs-a-cohort-study
#17
John-Michael Gamble, Jennifer R Donnan, Eugene Chibrikov, Laurie K Twells, William K Midodzi, Sumit R Majumdar
AIMS: Mixed evidence exists for the effect of incretin-based therapies on osteoporosis in type-2 diabetes. Therefore, we conducted a cohort study to determine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and common osteoporotic "fragility fractures" (upper extremity, hip, spine). METHODS: The UK-based Clinical Practice Research Datalink was used to identify adults without prior fractures receiving a new anti-diabetic drug or a new type-2 diabetes diagnosis between 2007 and 2016...
December 16, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29258504/dipeptidyl-peptidase-4-inhibitor-decreases-the-risk-of-atrial-fibrillation-in-patients-with-type-2-diabetes-a-nationwide-cohort-study-in-taiwan
#18
Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See
BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. METHODS: Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan's National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled...
December 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29258218/in-vitro-investigation-of-the-interaction-of-tolbutamide-and-losartan-with-human-serum-albumin-in-hyperglycemia-states
#19
Agnieszka Szkudlarek, Danuta Pentak, Anna Ploch, Jadwiga Pożycka, Małgorzata Maciążek-Jurczyk
Serum albumin is exposed to numerous structural modifications which affect its stability and activity. Glycation is one of the processes leading to the loss of the original properties of the albumin and physiological function disorder. In terms of long lasting states of the hyperglycemia, Advanced Glycation End-products (AGEs) are formed. AGEs are responsible for cellular and tissue structure damage that cause the appearance of a number of health consequences and premature aging. The aim of the present study was to analyze the conformational changes of serum albumin by glycation-"fructation"-using multiple spectroscopic techniques, such as absorption (UV-Vis), fluorescence (SFM), circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy and evaluate of possible alteration of binding and competition between tolbutamide (TB, a first-generation sulfonylurea oral hypoglycemic drug) and losartan (LOS, an angiotensin II receptor (AT₁) blocker used in hypertension (1st line with a coexisting diabetes)) in binding to non-glycated (HSA) and glycated (gHSAFRC) human serum albumin in high-affinity binding sites...
December 17, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29242349/efficacy-and-safety-of-itca-650-a-novel-drug-device-glp-1-receptor-agonist-in-type-2-diabetes-uncontrolled-with-oral-antidiabetes-drugs-the-freedom-1-trial
#20
Julio Rosenstock, John B Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Holly Huang, Michelle A Baron
OBJECTIVE: ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously for 3-6 months. Two doses of ITCA 650 were compared with placebo in patients with uncontrolled type 2 diabetes. RESEARCH DESIGN AND METHODS: This 39-week, phase 3, double-blind, placebo-controlled trial randomized 460 patients aged 18-80 years with glycated hemoglobin (HbA1c) 7.5-10% [58-86 mmol/mol] 1:1:1 to placebo, ITCA 650 40 μg/day, or ITCA 650 60 μg/day. Primary end point was change in HbA1c at 39 weeks...
December 14, 2017: Diabetes Care
keyword
keyword
109494
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"